Pacemaker current inhibition in experimental human cardiac sympathetic activation: a double-blind, randomized, crossover study
Publication year
2014Source
Clinical Pharmacology and Therapeutics, 95, 6, (2014), pp. 601-7ISSN
Publication type
Article / Letter to editor
Display more detailsDisplay less details
Organization
Laboratory Medicine
Laboratory of Genetic, Endocrine and Metabolic Diseases
Journal title
Clinical Pharmacology and Therapeutics
Volume
vol. 95
Issue
iss. 6
Page start
p. 601
Page end
p. 7
Subject
Radboudumc 17: Women's cancers RIHS: Radboud Institute for Health SciencesAbstract
Hyperpolarization-activated, cyclic nucleotide-gated 4 (HCN4) channels comprise the final pathway for autonomic heart rate (HR) regulation. We hypothesized that HCN4 inhibition could reverse autonomic imbalance in a human model of cardiac sympathetic activation. Nineteen healthy men ingested oral metoprolol+reboxetine, ivabradine+reboxetine, or placebo+reboxetine in a double-blind, randomized, crossover fashion. We assessed HR, blood pressure (BP), stroke volume, and cardiac output during rest and profound orthostatic stress. HR variability, BP variability, and baroreflex sensitivity were analyzed. Metoprolol, but not ivabradine, decreased resting HR and BP. Ivabradine attenuated the HR increase to orthostatic stress, albeit to a lesser extent than metoprolol. Stroke volume and cardiac output at a given HR were significantly lower with metoprolol. Unlike metoprolol, ivabradine did not affect HR variability, BP variability, or baroreflex sensitivity. Ivabradine attenuates sympathetic influences on HR at the sinus node level, leaving myocardial sympathetic activation unopposed. Reversal of parasympathetic dysfunction by ivabradine appears limited.
This item appears in the following Collection(s)
- Academic publications [246205]
- Faculty of Medical Sciences [93266]
Upload full text
Use your RU credentials (u/z-number and password) to log in with SURFconext to upload a file for processing by the repository team.